IRIS
GHIA, PAOLO PROSPERO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 9.733
EU - Europa 9.521
NA - Nord America 9.336
SA - Sud America 2.585
Continente sconosciuto - Info sul continente non disponibili 582
AF - Africa 203
OC - Oceania 25
Totale 31.985
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.830
RU - Federazione Russa 4.840
SG - Singapore 3.318
CN - Cina 2.959
BR - Brasile 2.098
IT - Italia 1.778
HK - Hong Kong 1.435
SE - Svezia 1.040
VN - Vietnam 853
FR - Francia 477
BD - Bangladesh 468
DE - Germania 373
CA - Canada 204
GB - Regno Unito 201
AR - Argentina 199
FI - Finlandia 165
IN - India 156
NL - Olanda 154
MX - Messico 129
AT - Austria 118
EC - Ecuador 99
IE - Irlanda 74
ID - Indonesia 70
ZA - Sudafrica 67
PL - Polonia 66
IQ - Iraq 61
JP - Giappone 52
CO - Colombia 48
TR - Turchia 48
ES - Italia 44
PK - Pakistan 41
PY - Paraguay 40
JM - Giamaica 38
MY - Malesia 35
VE - Venezuela 34
MA - Marocco 33
AE - Emirati Arabi Uniti 32
CR - Costa Rica 32
UA - Ucraina 31
SA - Arabia Saudita 26
CL - Cile 24
KE - Kenya 24
AU - Australia 22
CH - Svizzera 21
EG - Egitto 21
LT - Lituania 20
UZ - Uzbekistan 20
PE - Perù 19
TN - Tunisia 18
HN - Honduras 17
IL - Israele 15
SV - El Salvador 15
AZ - Azerbaigian 14
PH - Filippine 14
TT - Trinidad e Tobago 14
UY - Uruguay 14
BE - Belgio 13
DK - Danimarca 13
MD - Moldavia 13
NI - Nicaragua 13
TH - Thailandia 13
NP - Nepal 12
BO - Bolivia 10
KZ - Kazakistan 10
DZ - Algeria 9
GT - Guatemala 9
IR - Iran 9
KR - Corea 9
GR - Grecia 8
JO - Giordania 8
PT - Portogallo 8
RS - Serbia 8
AL - Albania 7
DO - Repubblica Dominicana 7
KW - Kuwait 7
PA - Panama 7
TW - Taiwan 7
BG - Bulgaria 6
BH - Bahrain 6
CZ - Repubblica Ceca 6
HU - Ungheria 6
AO - Angola 5
BB - Barbados 5
NO - Norvegia 5
OM - Oman 5
SN - Senegal 5
BY - Bielorussia 4
CY - Cipro 4
ET - Etiopia 4
GD - Grenada 4
LB - Libano 4
LU - Lussemburgo 4
MV - Maldive 4
RO - Romania 4
AM - Armenia 3
BS - Bahamas 3
GA - Gabon 3
KG - Kirghizistan 3
LV - Lettonia 3
PS - Palestinian Territory 3
Totale 31.357
Salva come PNG Salva come JPEG
Città #
Dallas 2.112
Singapore 1.465
Hong Kong 1.427
Moscow 1.154
San Jose 1.101
Ashburn 914
Council Bluffs 583
Shanghai 493
Hefei 435
Milan 418
Lauterbourg 382
Beijing 335
Lawrence 328
Princeton 328
Ho Chi Minh City 310
New York 281
Santa Clara 208
Hanoi 180
Los Angeles 180
Rome 179
São Paulo 170
Phoenix 163
Nuremberg 143
Helsinki 89
Munich 75
Dublin 72
Boardman 66
Brooklyn 62
Rio de Janeiro 55
Warsaw 55
Orem 53
Guangzhou 51
Vienna 51
Chicago 50
Houston 50
Buffalo 49
Mexico City 48
Naples 48
Denver 44
Brasília 43
Montreal 42
Da Nang 41
Tokyo 41
Atlanta 39
Belo Horizonte 39
Hangzhou 39
London 39
Chennai 37
Johannesburg 37
Palermo 37
Guayaquil 36
Lappeenranta 36
The Dalles 35
Curitiba 34
Seattle 34
Turku 34
Boston 33
Xi'an 32
Haiphong 30
Stockholm 30
Frankfurt am Main 29
Porto Alegre 29
Columbus 28
Poplar 28
Quito 27
Toronto 27
Turin 27
Philadelphia 26
Bari 25
Tianjin 25
Florence 24
Las Vegas 24
Manchester 23
Mumbai 23
San José 23
Washington 23
Amsterdam 22
Bologna 22
Charlotte 22
Dubai 22
Miami 22
Nairobi 22
Shenzhen 22
Baghdad 20
Ribeirão Preto 20
Ridgewood 20
Salvador 20
Thái Bình 20
Hải Dương 19
Kingston 19
Tashkent 19
Campinas 18
Manaus 18
San Francisco 18
Venice 18
Cleveland 17
Dhaka 17
Pune 17
Ankara 16
Catania 16
Totale 15.852
Salva come PNG Salva come JPEG
Nome #
Rugarli. Medicina interna sistematica 783
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice: Lymphoma 458
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort 433
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker: CHRONIC LYMPHOCYTIC LEUKEMIA 433
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study 299
3D-culture of CLL cells in bioreactor identifies the bone marrow as a key regulator of HS1 function in response to Ibrutinib 217
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) 211
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency 184
3D co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents 155
A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression 154
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial 146
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia 145
Chronic lymphocytic leukaemia 136
Cumulative review of cardiac failure with acalabrutinib in the treatment of chronic lymphocytic leukemia using data from clinical trials and postmarketing experience 128
A novel Rag2(-/-)gamma(-/-)(c)-xenograft model of human CLL 128
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia 126
A novel molecular complex expressed on immature B cells: A possible role in T cell-independent B cell development 122
Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models 122
3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells 122
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage 121
Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection 119
Supplementary Data from Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models 118
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL 118
A screening study of Chlamydia psittaci infection in 172 cases of nodal and extranodal non-hodgkin lymphomas 116
Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models 115
Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death 113
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia 113
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 112
A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study 111
A new life for rituximab? 111
ABVD CAN BE SAFELY ADMINISTERED REGARDLESS OF ABSOLUTE NEUTROPHIL COUNT AND WITHOUT G-CSF SUPPORT IN HODGKIN'S LYMPHOMA PATIENTS 111
Similar epidemiological trends of pre-neoplastic precursors and their respective lymphoid malignancies in Taiwan 110
Pathogen-specific B-cell receptors drive chronic lymphocytic leukemia by light-chain-dependent cross-reaction with autoantigens 110
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia 109
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor 109
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 109
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study 109
A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence 108
Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL 107
A woman and her canary: a tale of chlamydiae and lymphomas 107
Chronic lymphocytic leukemia 106
A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia? 105
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL 104
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib 103
IκBε deficiency accelerates disease development in chronic lymphocytic leukemia 103
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia 103
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine 103
CD4+T cells sustain aggressive chronic lymphocytic leukemia in Em- TCL1 mice through a CD40L-independent mechanism 102
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials 101
B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia 100
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes 100
A frequent EcoRI polymorphism in the bcl-2 gene 99
In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors 99
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment 99
CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL 98
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 98
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. 98
A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia 97
Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. 96
Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece 96
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia 95
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications 95
Monoclonal B-cell lymphocytosis: right track or red herring? 95
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients 95
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib 95
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 95
T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations 94
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results 93
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 93
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis 93
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA 93
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial 92
MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27 92
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee 91
PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target 91
Targeting B-cell anergy in chronic lymphocytic leukemia. 91
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: Analysis within prospective clinical trials of the German CLL Study Group 91
Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis 90
Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia 90
Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms 89
Iron causes lipid oxidation and inhibits proteasome function in multiple myeloma cells: A proof of concept for novel combination therapies 88
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion 88
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling 87
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience 86
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x) 85
Distinct Innate Immunity Pathways to Activation and Tolerance in Subgroups of Chronic Lymphocytic Leukemia with Distinct Immunoglobulin Receptors. 85
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia 85
[Cellular and molecular mechanisms conditioning the accumulation of resting neoplastic cells in B-lymphocyte chronic lymphatic leukemia] 85
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 83
Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients 83
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 82
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 82
MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL 82
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) 82
Reprogramming cell death: BCL2 family inhibition in hematological malignancies 81
ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor 81
Ascend: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia 81
CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL) 81
COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now 80
Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia 80
Totale 12.388
Salva come PNG Salva come JPEG
Categoria #
all - tutte 191.723
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 191.723
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022193 0 0 0 79 28 6 17 17 16 9 6 15
2022/20231.988 758 410 124 3 39 254 71 111 85 32 34 67
2023/2024903 42 58 49 182 68 127 22 59 4 27 87 178
2024/20255.807 694 112 102 154 141 433 620 465 1.211 952 426 497
2025/202619.747 1.329 1.973 2.178 2.690 1.196 513 1.625 1.268 4.495 996 574 910
2026/20273.089 864 1.734 491 0 0 0 0 0 0 0 0 0
Totale 31.985